Seek Returns

AMGN vs. EXEL: Amgen vs. Exelixis Stock Comparison

How do Amgen (AMGN) and Exelixis (EXEL) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Amgen (AMGN) and Exelixis (EXEL) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Amgen (AMGN) and Exelixis (EXEL)
Profile ItemAMGNEXEL
NameAmgen Inc. Common StockExelixis Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization249.05 billion USD16.98 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 17, 1983April 17, 2000
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

AMGN
EXEL
GSPC
Loading price history…
Amgen (AMGN) vs. Exelixis (EXEL), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Amgen (AMGN) and Exelixis (EXEL). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Amgen (AMGN) and Exelixis (EXEL). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Amgen (AMGN) and Exelixis (EXEL)
MetricAMGNEXEL
Total Return (1Y)48.82%74.98%
Total Return (3Y, Annualized)24.31%50.33%
Total Return (5Y, Annualized)20.67%31.10%

Risk Profile

Drawdown History

AMGN
EXEL
GSPC
Loading price history…
Amgen (AMGN) vs. Exelixis (EXEL), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Amgen (AMGN) and Exelixis (EXEL). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Amgen (AMGN) and Exelixis (EXEL)
MetricAMGNEXEL
Volatility (1Y, Annualized)29.12%34.17%
Beta (5Y)0.430.41
Max Drawdown (5Y)-24.86%-35.41%
Avg. Volume (3M)2.76M2.33M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
AMGN and EXEL are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Amgen (AMGN) and Exelixis (EXEL)
MetricAMGNEXEL
Sharpe Ratio (1Y)1.532.07
Sortino Ratio (1Y)2.363.23

Profitability

ROE (TTM)

Both Amgen (AMGN) at 78.35% and Exelixis (EXEL) at 44.32% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

78.35%

Max
109.18%
AMGN
78.35%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.32%

Max
109.18%
EXEL
44.32%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Amgen (AMGN) vs. Exelixis (EXEL): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Amgen (AMGN) at 24.14% and Exelixis (EXEL) at 35.45% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.14%

AMGN
24.14%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.45%

EXEL
35.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Amgen (AMGN) vs. Exelixis (EXEL): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Amgen (AMGN) at 35.79% and Exelixis (EXEL) at 40.75% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.79%

Max
83.12%
AMGN
35.79%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.75%

Max
83.12%
EXEL
40.75%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Amgen (AMGN) vs. Exelixis (EXEL): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Amgen (AMGN) and Exelixis (EXEL)
MetricAMGNEXEL
ROE (TTM)78.35%44.32%
ROA (TTM)8.91%23.52%
Net Margin (TTM)24.14%35.45%
Operating Margin (TTM)35.79%40.75%
Gross Margin (TTM)72.47%96.26%

Growth

Revenue Growth

Both Amgen (AMGN) at 9.95% and Exelixis (EXEL) at 6.98% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Amgen (AMGN) vs. Exelixis (EXEL): A comparison of their Revenue Growth across different time periods.

EPS Growth

Amgen (AMGN) at 88.23% sits in the top EPS growth quartile, while Exelixis (EXEL) at 57.95% is closer to the peer norm — faster per-share earnings growth for AMGN.

Loading chart…
Amgen (AMGN) vs. Exelixis (EXEL): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Amgen (AMGN) and Exelixis (EXEL)
MetricAMGNEXEL
Revenue Growth (YoY)9.95%6.98%
Revenue Growth (3Y CAGR)11.77%12.93%
EPS Growth (YoY)88.23%57.95%
EPS Growth (3Y CAGR)5.52%70.59%

Financial Strength

Current Ratio (MRQ)

Exelixis (EXEL) at 3.21 keeps current ratio within its industry’s typical mid-range, while Amgen (AMGN) at 1.48 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AMGN.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.48

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
AMGN
1.48
Min
0.10

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.21

Max
25.13
Q3
12.13
Median
5.52
EXEL
3.21
Q1
2.47
Min
0.10
Loading chart…
Amgen (AMGN) vs. Exelixis (EXEL): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Exelixis (EXEL) at 0.09 is near its industry mid-range for debt-to-equity ratio, while Amgen (AMGN) at 3.76 sits above its benchmark range, pointing to a heavier debt load relative to equity.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.76

AMGN
3.76
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
EXEL
0.09
Q1
0.02
Min
0.00
Loading chart…
Amgen (AMGN) vs. Exelixis (EXEL): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Amgen (AMGN) and Exelixis (EXEL)
MetricAMGNEXEL
Current Ratio (MRQ)1.483.21
Debt / Equity (MRQ)3.760.09
Net Debt / EBITDA2.31-0.71

Dividends

Dividend Yield (TTM)

Exelixis (EXEL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a yield of 2.16%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.16%

AMGN
2.16%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Exelixis (EXEL): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Exelixis (EXEL) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a payout of 57.62%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.62%

AMGN
57.62%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Exelixis (EXEL): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Amgen (AMGN) and Exelixis (EXEL)
MetricAMGNEXEL
Dividend Yield (TTM)2.16%0.00%
Dividend Payout Ratio (TTM)57.62%0.00%

Valuation

P/E Ratio (TTM)

Both Amgen (AMGN) at 26.69 and Exelixis (EXEL) at 20.83 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.69

Max
85.34
Q3
43.46
AMGN
26.69
Median
26.69
Q1
13.30
Min
0.07

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.83

Max
85.34
Q3
43.46
Median
26.69
EXEL
20.83
Q1
13.30
Min
0.07
Loading chart…
Amgen (AMGN) vs. Exelixis (EXEL): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Amgen (AMGN) at 6.40 and Exelixis (EXEL) at 6.80 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.40

Max
58.18
Q3
25.77
Median
7.30
AMGN
6.40
Q1
3.01
Min
0.01

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.80

Max
58.18
Q3
25.77
Median
7.30
EXEL
6.80
Q1
3.01
Min
0.01
Loading chart…
Amgen (AMGN) vs. Exelixis (EXEL): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Exelixis (EXEL) at 9.28 sits in the upper P/B ratio quartile, and Amgen (AMGN) at 17.35 prices even higher, above its industry range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.35

AMGN
17.35
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.28

Max
13.53
EXEL
9.28
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Amgen (AMGN) vs. Exelixis (EXEL): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Amgen (AMGN) and Exelixis (EXEL)
MetricAMGNEXEL
P/E Ratio (TTM)26.6920.83
P/S Ratio (TTM)6.406.80
P/B Ratio (MRQ)17.359.28
Free Cash Flow Yield (TTM)2.96%4.47%